Osteoprotegerin,
an endogenous

antiosteoclast factor

for protecting bone in
rheumatoid arthritis. Bolon
B, Shalhoub V, Kostenuik PJ,

et al. Arthritis Rheumatism 46:
3121-3135, 2002. PMID: 12483715

 Repair of local bone erosions and reversal

of systemic bone loss upon combination therapy

with anti-TNF, OPG and PTH in TNF-mediated arthritis.

Redlich K, Gortz B, Hayer S, et al. Am J Pathol

164: 543-555, 2004. PMID: 14742260

Receptor activator of nuclear factor KB ligand (RANKL) and osteoprotegerin (OPG): the yin and yang of joint integrity. 

Bolon B, Shalhoub V, Kostenuik PJ, Zack D, Feige U. 

Cytokines and Joint Injury (van den Berg WB, Miossec P, eds.)
Birkhäuser Verlag, Basel, pp. 221-267, 2004.

Additive bone-protective effects of anabolic treatment when

used in conjunction with RANKL and tumor necrosis factor inhibition

in two rat arthritis models. Schett G, Middleton S, Bolon B, et al.

Arthritis and Rheumatism 52: 1604-1611, 2005. PMID: 15880601

RANKL is a marker and mediator of local and systemic bone loss in two

rat models of inflammatory arthritis. Stolina S, Adamu S, Schett G, et al.

J Bone Miner Res 20: 1756-1765, 2005. PMID: 16160733

RANKL inhibition by OPG prevents focal bone erosions in arthritic rats without inducing renal pathology: Comparison with zoledronic acid. Stolina M, Ominsky MS, Middleton S, Adamu S, Dywer D, Asuncion F, Geng Z, Zack D, McDormand D, Kostenuik PJ.  Arthritis and Rheumatism 20 (Suppl) S157, 2005 (Abstract).

 The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis. Stolina M, Bolon B, Middleton S, et al. Biomarkers 13: 692-712, 2008. PMID: 19096963

 The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis. Stolina M, Bolon B, Middleton S, Dwyer D, et al. J Clin Immunol 29: 158-174, 2009.

PMID: 18726678

Prevention of glucocorticoid-induced bone loss by inhibition of RANKL. Hofbauer LC, Zeitz U, Schoppet M, et al. Arthritis and Rheumatism 60: 1427-1437, 2009. PMID: 19404943

 Tumor necrosis factor α and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis. Schett G, Stolina M, Dwyer D, et al. Arthritis and Rheumatism 60: 2644-2654, 2009.

PMID: 19714640

 RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNF-alpha or anti-IL-1 therapies. Stolina M, Schett G, Dwyer D, et al.Arthr Res Ther 11: R187 (doi:10.1186/ar2879), 2009. PMID: 20003323

Some of Dr. Kostenuik's publications in
the arthritis field:

Rheumatoid arthritis, a potentially crippling autoimmune disease, can lead to peri-articular bone loss and focal bone erosions, as well as systemic bone loss.  These skeletal disease sequellae triggered Paul's interest in arthritis pathophysiology and treatment strategies.

Arthritis